Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer

Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102—Final report.

(2017) S. Shahda et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).

(2017) A. R. Townsend et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy

(2016) H. S. Rugo et al.   ANNALS OF ONCOLOGY

Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): Results of the SWISH trial.

(2016) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Abstracts of the MASCC/ISOO 2016 Annual Meeting

(2016)   SUPPORTIVE CARE IN CANCER

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

(2014) Filip Janku et al.   Cell Reports

Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

(2013) K. Ng et al.   CLINICAL CANCER RESEARCH

Coexistent mutations ofKRASandPIK3CAaffect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer

(2013) Areumnuri Kim et al.   INTERNATIONAL JOURNAL OF CANCER

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer

(2013) B. M. Wolpin et al.   ONCOLOGIST

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations

(2012) Filip Janku et al.   JOURNAL OF CLINICAL ONCOLOGY

KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors

(2012) Ignacio Garrido-Laguna et al.   PLoS One

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

(2011) Andrea L. Harzstark et al.   CANCER

Pathologic Scoring of PTEN Immunohistochemistry in Endometrial Carcinoma is Highly Reproducible

(2011) Karuna Garg et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer

(2011) I. Altomare et al.   ONCOLOGIST

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

(2010) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL INVESTIGATION

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers

(2008) Ludovic Barault et al.   INTERNATIONAL JOURNAL OF CANCER

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY